- Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
-
Nguyen VH, Nguyen MH
- KMID: 2560108
- Clin Mol Hepatol.
- 2024 Oct;30(4):1000-1001.
- doi: 10.3350/cmh.2024.0611
-
- CITED
-
- Close
- SHARE
-
- Close
- In response to: Steatotic liver disease-know your enemies
-
Le MH, Henry L, Nguyen MH
- KMID: 2554439
- Clin Mol Hepatol.
- 2024 Apr;30(2):284-286.
- doi: 10.3350/cmh.2024.0108
-
- CITED
-
- Close
- SHARE
-
- Close
- Beyond Medical Bills: High Prevalence of Financial Toxicity and Diverse Management Strategies Among Vietnamese Patients With Cancer
-
Tran BT, Nguyen TG, Le DD, Nguyen MT, Nguyen NPT, Nguyen MH, Ong TD
- KMID: 2558160
- J Prev Med Public Health.
- 2024 Jul;57(4):407-419.
- doi: 10.3961/jpmph.24.090
Objectives: This study was conducted to measure financial toxicity (FT) among patients with cancer in Vietnam using the COmprehensive Score for financial Toxicity (COST) and to describe the cost management... -
- CITED
-
- Close
- SHARE
-
- Close
- Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study
-
Nguyen VH, Le I, Ha A, Le RH, Rouillard NA, Fong A, Gudapati S, Park JE, Maeda M, Barnett S, Cheung R, Nguyen MH
- KMID: 2546387
- Clin Mol Hepatol.
- 2023 Oct;29(4):1002-1012.
- doi: 10.3350/cmh.2023.0205
Background/Aims: Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal... -
- CITED
-
- Close
- SHARE
-
- Close
- Nonalcoholic fatty liver disease and non-liver comorbidities
-
Manikat R, Nguyen MH
- KMID: 2539793
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):s86-s102.
- doi: 10.3350/cmh.2022.0442
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by excess fat accumulation in the liver. It is closely associated with metabolic syndrome, and patients with NAFLD often... -
- CITED
-
- Close
- SHARE
-
- Close
- Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
-
Ng CH, Huang DQ, Nguyen MH
- KMID: 2534343
- Clin Mol Hepatol.
- 2022 Oct;28(4):790-801.
- doi: 10.3350/cmh.2022.0070
Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world’s adult population and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
-
Le MH, Le DM, Baez TC, Dang H, Nguyen VH, Lee K, Stave CD, Ito T, Wu Y, Yeo YH, Ji F, Cheung R, Nguyen MH
- KMID: 2554429
- Clin Mol Hepatol.
- 2024 Apr;30(2):235-246.
- doi: 10.3350/cmh.2023.0485
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events. Methods: We performed a systematic review... -
- CITED
-
- Close
- SHARE
-
- Close
- Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
-
Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, Nguyen MH
- KMID: 2534349
- Clin Mol Hepatol.
- 2022 Oct;28(4):841-850.
- doi: 10.3350/cmh.2022.0239
Background/Aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD.... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment
-
Oh H, Jun DW, Saeed WK, Nguyen MH
- KMID: 2373132
- Clin Mol Hepatol.
- 2016 Sep;22(3):327-335.
- doi: 10.3350/cmh.2016.0049
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is... -
- CITED
-
- Close
- SHARE
-
- Close
- Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
-
Rouillard NA, Barnett SD, Zhang X, Kam L, Manikat R, Cheung R, Nguyen MH
- KMID: 2563422
- Clin Mol Hepatol.
- 2025 Jan;31(1):227-239.
- doi: 10.3350/cmh.2024.0564
Background/Aims: With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Screening of Endophytic Fungal Isolates Against Raffaelea quercus-mongolicae Causing Oak Wilt Disease in Korea
-
Nguyen MH, Yong JH, Sung HJ, Lee JK
- KMID: 2509512
- Mycobiology.
- 2020 Dec;48(6):484-494.
- doi: 10.1080/12298093.2020.1830486
Oak wilt disease caused by Raffaelea quercus-mongolicae has emerged obviously in Korea. We selected antifungal isolates against R. quercus-mongolicae among 368 endophytic fungal isolates from different parts of oak and... -
- CITED
-
- Close
- SHARE
-
- Close
- Fungal Community Analyses of Endophytic Fungi from Two Oak Species, Quercus mongolica and Quercus serrata, in Korea
-
Nguyen MH, Shin KC, Lee JK
- KMID: 2520572
- Mycobiology.
- 2021 Aug;49(4):385-395.
- doi: 10.1080/12298093.2021.1948175
Fungal endophytes have been recorded in various plant species with a richness of diversity, and their presence plays an essential role in host plant protection against biotic and abiotic stresses.... -
- CITED
-
- Close
- SHARE
-
- Close
- Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
-
Lee HY, Jun DW, Kim HJ, Oh H, Saeed WK, Ahn H, Cheung RC, Nguyen MH
- KMID: 2441009
- Korean J Intern Med.
- 2019 Mar;34(2):296-304.
- doi: 10.3904/kjim.2017.194
BACKGROUND/AIMS: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
-
Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, Fang YJ, Yang TH, Nguyen MH, Lin JT, Hsu YC
- KMID: 2549386
- Clin Mol Hepatol.
- 2024 Jan;30(1):98-108.
- doi: 10.3350/cmh.2023.0194
Background/Aims: Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring... -
- CITED
-
- Close
- SHARE
-
- Close
